16 |
Klinisk Biokemi i Norden · 3 2018
Foto: Henrik Alfthan.
16. Gegenhuber A, Struck J, Poelz W, Pacher R,
Morgenthaler NG, Bergmann A, Haltmayer M,
Mueller T. Midregional pro-A-type natriuretic
peptide measurements for diagnosis of acute
destabilized heart failure in short-of-breath
patients: comparison with B-type natriuretic
peptide (BNP) and amino-terminal proBNP.
Clin Chem 2006;52:827-31.
17. Hunter I, Alehagen U, Dahlström U, Rehfeld
JF, Crimmins DL, Goetze JP. N-terminal
pro-atrial natriuretic peptide measurement in
plasma suggests covalent modification. Clin
Chem 2011;57:1327-30.
18. Maisel A, Mueller C, Nowak R, Peacock WF,
Landsberg JW, Ponikowski P, et. al D. Mid-
region pro-hormone markers for diagnosis
and prognosis in acute dyspnea: results from
the BACH (Biomarkers in Acute Heart Failure)
trial. J Am Coll Cardiol 2010;55:2062-76.
19. McKie PM, Burnett JC Jr. NT-proBNP: The
Gold Standard Biomarker in Heart Failure. J
Am Coll Cardiol 2016;68:2437-2439.
20. York MK, Gupta DK, Reynolds CF, Farber-
Eger E, Wells QS, Bachmann KN, et. al. B-Type
Natriuretic Peptide Levels and Mortality in
Patients With and Without Heart Failure. J
Am Coll Cardiol 2018;71:2079-2088.
21. Topol EJ. Nesiritide - not verified. N Engl J
Med 2005;353:113-6.
22. Nawarskas JJ, Anderson JR. Omapatrilat: a
unique new agent for the treatment of car-
diovascular disease. Heart Dis 2000;2:266-
74.
23. McMurray JJ, Packer M, Desai AS, Gong J, Lef-
kowitz MP, Rizkala AR, et. al; PARADIGM-HF
Investigators and Committees. Angiotensin-
neprilysin inhibition versus enalapril in heart
failure. N Engl J Med 2014;371:993-1004.
